Studies have shown significantly elevated levels of PF-4 and β-TG in the serum of patients with AD compared to the control group, correlating with the severity of clinical symptoms, suggesting their potential role as biomarkers of disease activity [66,72,73]. Here, PF4 is linked to Alzheimer disease.